Oct 23rd, 2024
Cutting-edge science highlights #AHA24
#AHA24 has slated presentation of 29 Late-Breaking Science results and 29 Featured Science studies during the meeting.
Late-Breaking Science
LBS.01: Late-Breaking Science 1
8:30-9:45 a.m. | Saturday, Nov. 16 | Main Event I
- Effects of Intensive Blood Pressure Control in Patients With Type 2 Diabetes (BPROAD)
- Tirzepatide for Patients With Heart Failure With Preserved Ejection Fraction and Obesity: the SUMMIT Trial
- Nexiguran Ziclumeran (nex-z, also known as NTLA-2001), an Investigational in Vivo CRISPR-Based Therapy for Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM): Interim Report of the Phase 1 Study
LBS.02: Late-Breaking Science 2
1:30-2:45 p.m. | Saturday, Nov. 16 | Main Event I
- Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia in Ischemic Cardiomyopathy (VANISH2)
- Randomized Comparison of Left Atrial Appendage Closure With Oral Anticoagulation After Catheter Ablation for Atrial Fibrillation (OPTION)
- Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in Atrial Fibrillation (BRAIN AF)
LBS.03: Late-Breaking Science 3
3:15-4:30 p.m. | Saturday, Nov. 16 | Main Event I
- Evaluation of Randomized Audit and Feedback to Increase Heart Failure Medication Optimization Among Primary Care Pharmacists in the Veterans Affairs Health Care System (PHARM-HF A&F Study)
- Novel AI to Assess Intracardiac Filling Pressure: The Noninvasive SEISMocardiogram in Cardiovascular Monitoring for Heart Failure I (SEISMIC-HF I) Study
- Artificial Intelligence-Based Automated ECHOcardiographic Measurements and the Workflow of Sonographers (AI-ECHO): Randomized Crossover Trial
- PanEcho: Complete AI-enabled Echocardiography Interpretation With Multitask Deep Learning
LBS.04: Late-Breaking Science 4
8-9:15 a.m. | Sunday, Nov. 17 | Main Event I
- Efficacy of Restrictive vs. Liberal Oxygenation in Patients Undergoing Coronary Artery Bypass Grafting or Aortic Valve Replacement: A Randomized Clinical Trial (GLORIOUS)
- Efficacy of a Glucagon-Like Peptide-1 Agonist in Patients Undergoing Coronary Artery Bypass Grafting or Aortic Valve Replacement: A Randomized Clinical Trial (GLORIOUS)
- Efficacy and Safety of Edoxaban in Anticoagulant Therapy Early After Surgical Bioprosthetic Valve Replacement: ENBALV Trial
- The CLEAR SYNERGY (OASIS 9) Trial: A 2x2 Factorial Randomized Controlled Trial of Colchicine vs. Placebo and Spironolactone vs. Placebo in Patients With Myocardial Infarction: The Results of the Spironolactone Factorial
LBS.05: Late-Breaking Science 5
3:30-4:45 p.m. | Sunday, Nov. 17 | Main Event I
- TOPSPIN- A Three-Arm Randomized Trial for Treatment Optimization of Blood Pressure With Single-Pill Combinations In India
- Electronic Nudges to Increase Influenza Vaccination Among Patients With History of Myocardial Infarction: Insights From 3 Randomized Clinical Trials Enrolling >2 Million Patients (NUDGE-FLU)
- Pragmatic Randomized Controlled Trial of a Decision Support System to Aid Physician Optimization of Early Lipid Lowering Therapies After Acute Coronary Syndrome (ZODIAC)
- Preliminary Results of Randomized Trial of New vs. Reconditioned Pacemakers for Patients Unable to Obtain a New Device in Low- and Middle-Income Countries: The My Heart Your Heart (MHYH) Randomized Trial
LBS.06: Late-Breaking Science
8-9:15 a.m. | Monday, Nov. 18 | Main Event I
- Myeloperoxidase Inhibition With Mitiperstat in Heart Failure With Preserved and Mildly Reduced Ejection Fraction: Primary Results From the ENDEAVOR Randomized Clinical Trial
- Effects of Sacubitril-Valsartan on Prevention of Cardiotoxicity in High-Risk Patients Undergoing Anthracycline Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial: The SARAH Trial
- Novel Bumetanide Nasal Spray (BNS) Demonstrates Safety, Tolerability and Equivalent Efficacy Compared to Intravenous and Oral Bumetanide (RSQ-777-02)
- Sodium Zirconium Cyclosilicate and MRA Optimization in Heart Failure With Reduced Ejection Fraction and Hyperkalemia: Main Results From REALIZE-K Randomized Controlled Trial
LBS.07: Late-Breaking Science 7
9:45-11 a.m. | Monday, Nov. 18 | Main Event I
- Comparison of Linear Ablation Plus Pulmonary Vein Isolation vs. Pulmonary Vein Isolation Alone for Persistent Atrial Fibrillation: Results From the PROMPT-AF Randomized Trial
- Cryoballoon Ablation vs. Radiofrequency Ablation in Patients With Persistent Atrial Fibrillation (CRRF-PeAF): A Prospective, Multicenter, Randomized, Noninferiority Clinical Trial
- Randomized Controlled Trial of Metformin and Lifestyle/Risk Factor Modification for Upstream Prevention of Atrial Fibrillation Progression: The Targeting Risk Interventions and Metformin for Atrial Fibrillation (TRIM-AF) Trial
- Aggressive Risk Factor Reduction Study for Atrial Fibrillation (ARREST-AF) Implications for Ablation Outcomes: A Randomized Clinical Trial
LBS.08: Late-Breaking Science 8
1:30-2:45 p.m. | Monday, Nov. 18 Main Event I
- ALPACAR Phase 2 Trial of Zerlasiran: Multiple Doses of a Short-Interfering RNA Targeting Lipoprotein(a) Over 60 weeks.
- A Randomized Phase 2 Trial of Muvalaplin: An Oral Disrupter of the Assembly of Lipoprotein(a) Particles (KRAKEN)
- Safety and Efficacy of Obicetrapib in Patients With Heterozygous Familial Hypercholesterolemia (BROOKLYN)
Featured Science
FS.01: Featured Science | Novel Approaches to Managing Lipid Risk
1:30-2:45 p.m. | Saturday, Nov. 16 | S100A
- Long-Term Efficacy of Lerodalcibep in 1,468 Patients at Very High and High Risk for CVD in the 72-Week Open-Label Extension Trial (LIBerate-OLE)
- Efficacy and Safety of Lerodalcibep, a Third-Generation PCSK9 Inhibitor, in 703 Heterozygous Familial Hypercholesterolemia Subjects in the Open Label Extension Trial (LIBerate-HeFH_OLE)
- PALISADE: A Phase 3 Study to Assess the Efficacy and Safety of Plozasiran in Adults With Genetically or Clinically Defined Familial Chylomicronemia Syndrome (FCS) at High Risk of Acute Pancreatitis (AP)
- Transcriptomic Signatures and Predictors of Evolocumab Added to Maximum Statin Therapy Based on Intra-Coronary Plaque Characteristics: YELLOW III Study
FS.02: Featured Science | Health Technology and the Future of Clinical Trials
1:30-2:45 p.m. | Saturday, Nov. 16 | S104B
- Natural Language Processing to Adjudicate Heart Failure Hospitalizations in Global Clinical Trials (DELIVER)
- Manual vs. AI-Assisted Clinical Trial Screening Using Large-Language Models (MAPS-LLM)
- Personalized App-Based Coaching Improves Physical Activity in Patients With HFpEF Compared to Standard Care: A Randomized Parallel Group Trial (MyoMobile Study)
- Impact of Technology-Enabled Home-Based Cardiac Rehabilitation on Functional Status and Cardiovascular Health Metrics: The American Heart Association Health Technology Network mTECH-Rehab Randomized Controlled Trial (mTECH-Rehab)
FS.03: Featured Science | Getting Closer to the Summit: New HFpEF Treatments
8-9:15 a.m. | Sunday, Nov. 17 | S100A
- Effect of Finerenone on a Hierarchical Composite Endpoint Analyzed Using Win Statistics in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of FINEARTS-HF
- Efficacy and Safety of Finerenone in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: A Prespecified Sex-Specific Analysis of the FINEARTS-HF Trial
- Finerenone and Risk of Hyperkalemia in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction (FINEARTS-HF)
- Effects of Tirzepatide on Cardiorenal End-Organ Damage in Heart Failure and Preserved Ejection Fraction: Insights From the SUMMIT Trial
FS.04: Featured Science | Vascular Outcomes in the Spotlight
8-9:15 a.m. | Monday, Nov. 18 | S100A
- Geographical Variations of Treatment Disparities Between Black and White Patients With Peripheral Artery Disease Across the United States
- Anatomically Directed Lower Extremity Gene Therapy for Ulcer Healing: A Double Blind, Randomized, Placebo Controlled Study (Legend 1 Trial)
- Bempedoic Acid and Limb Outcomes in Statin-Intolerant Patients With Peripheral Artery Disease: New Insights From the CLEAR OUTCOMES Trial
- Rivaroxaban for 18 Months vs. 6 Months in Cancer Patients With Low-Risk Pulmonary Embolism: ONCO PE Trial
FS.05: Featured Science | Amyloid, Hypertrophic and Danon Cardiomyopathies: Targeted Therapies and Specific Populations
9:45-11 a.m. | Monday, Nov. 18 | S103BC
- Danon Disease Phase 1 RP-A501 Results: The First Single-Dose Intravenous Gene Therapy With Recombinant Adeno-Associated Virus (AAV9:LAMP2B) for a Monogenic Cardiomyopathy
- Mavacamten Treatment in Patients With Obstructive HCM Referred for Septal Reduction Therapy: 128-Week Results From VALOR-HCM Trial
- Acoramidis Reduces All-Cause Mortality (ACM) and Cardiovascular-Related Hospitalization (CVH): Initial Outcomes From the ATTRibute-CM Open-Label Extension (OLE) Study
- Impact of Vutrisiran on Markers of Disease Progression in Patients With Transthyretin Amyloidosis With Cardiomyopathy in the HELIOS-B Trial
- The Prevalence of Transthyretin Cardiac Amyloidosis in Older Black and Hispanic Individuals With Heart Failure: The Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations Study (SCAN-MP)
- ATTR-Specific Medication in Dual Pathology Aortic Stenosis and Transthyretin Cardiac Amyloidosis
FS.06: Featured Science | Novel Insights in Cardiovascular Interventional Outcomes
1:30-2:45 p.m. | Monday, Nov. 18 |S 100A
- Semaglutide Improves Cardiovascular Outcomes in Patients With a History of Coronary Artery Bypass Surgery and Overweight or Obesity: The SELECT Trial
- Five-Year Results From the AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial (Amulet IDE)
- The Impact of Carbon Monoxide to Determine the In-Hospital Prognosis After Acute Coronary Syndrome (ADDICT-ICCU)
- Quantitative Assessment of Mitral Annular Calcification Severity Predicts Outcomes in Severe Aortic Stenosis Patients Undergoing Transcatheter Aortic Valve Replacement
FS.07: Featured Science | Incretion Modulation Is the Time Now for Standard of Care
1:30-2:45 p.m. | Monday, Nov. 18 | S103BC
- Effect of Tirzepatide on Cardiac Structure and Function in Obese HFpEF: the SUMMIT CMR Substudy
- Effects of Tirzepatide on the Clinical and Symptom Burden of Patients With Heart Failure and a Preserved Ejection Fraction: Results From the SUMMIT Trial
- Benefits of Semaglutide on Chronic Kidney Disease Outcomes by Cardiovascular Status or Risk in the FLOW trial
For more information about these and other #AHA24 sessions, refer to the Online Program Planner.
